Heron Therapeutics Inc HRTX reported Q3 sales of $31.43 million, missing the consensus of $32.75 million.
The company reported a Q3 EPS loss of $(0.17), lower than $(0.38) a year, and beating the consensus of $(0.29).
The company implemented a cost reduction plan to decrease operating expenses by 26% in 2023 compared to 2022, and full-year 2024 operating expenses to be around $108 million-$116 million.
The company sees FY23 sales of $123 million-$125 million compared to a prior range of $99 million-$103 million and a consensus of $124.61 million.
The company forecasts FY24 sales of $138 million-$158 million versus a consensus of $156.57 million.
Needham noted that the guidance parameters highlight the company's restructuring and cost reduction progress and map a path to operating cash flow breakeven by YE2024.
EBITDA targets hinges on the stability of the Chemotherapy Induced Nausea and Vomiting franchise and the growth of Zynrelef, which should see a label expansion in early 2024 and a vial access needle modification in September 2024.
Needham maintains the Buy rating with a price target of $4 and expects it will take a few quarters of execution and improving sales to demonstrate progress towards the proposed profitability path.
Price Action: HRTX shares are up 61.40% at $0.87 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
